Latest editorial
IAN LAVERY MP warns that decades of neoliberal policies have left former industrial communities behind — but a renewed Labour commitment to working people could change the political landscape
Held hostage by Big Pharma
Firms like Celgene make the NHS pay absurd prices for medicines that are cheap to make. They're telling us to pay up or watch people like me die, argues MIKE MARQUSEE
PAOLO SANTALUCIA reports on how an Italian region defies US pressure to end a Cuban doctors programme
HENRY FOWLER outlines the GFTU’s new 2026-27 education programme and argues that investing in trade union education is essential to building worker power, developing leaders and strengthening collective action
We need a government that invests in saving lives not destroying them, argues SOPHIE BOLT
More expensive by weight than gold, saffron is surprisingly simple to grow. MAT COWARD explains
The public inquiry is the result of more than a decade of determined campaigning. Now, those who fought for justice want the full story of government involvement and police conduct to be told, says KATE FLANNERY
The Durham Miners’ Gala is a celebration of working-class culture, but also a call to action — to rebuild workers’ collective strength, says KIM JOHNSON MP
In recent months I've been taking a medication called Revlimid, given as a "late therapy" for multiple myeloma.
Since it looks like I may be Revlimid-dependent for a while, I decided to educate myself about the drug. As the chemistry is beyond me, I focused my attention elsewhere.
The first thing I discovered was that Revlimid is phenomenally expensive.
Similar stories
CLAUDIA WEBBE says the horrific price British patients will pay for this NHS deal is now clear — and there’s time to get out of it, if MPs will only force the issue
With more people dying each year and many spending their final days in institutions, researchers argue that wider access to palliative care could offer a more humane and cost-effective alternative, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
Politicians who continue to welcome contracts with US companies without considering the risks and consequences of total dependency in the years to come are undermining the raison d’etre of the NHS, argues Dr JOHN PUNTIS